Bay Area's Adamas Pharma Pays Big Bucks to Double HQ
With the commercial launch of newly-approved Parkinson's disease treatment Gocovri, Bay Area drugmaker Adamas is growing. Source: BioSpace
3 Diabetes Biotechs That Could Surge 50% or More in 2018
Wall Street projects these three biotechs will grow the fastest over the next 12 months. Source: BioSpace
Deal Spree Continues as Celgene Nabs Juno in $9B Deal
The announcement sent shares of Juno soaring more than 27 percent in pre-market trading to $86.26. Source: BioSpace
Hepatares Co-Founder to Helm Merck's New R&D Center in the UK
Marshall co-founded more than a decade ago, and which was acquired by Sosei in 2015. Source: BioSpace
Sanofi CEO Finally Scores With $11.6B Buyout of Biogen's Spinoff Bioverativ
The deal has Sanofi paying $105 per share in cash. Source: BioSpace
Up-and-Coming Chinese Biotech BeiGene Gets $750M Worth of Love From U.S. Investors
The company will use the cash for working capital and general corporate purposes, including R&D activities. Source: BioSpace
New York's Tyme Jumps as Pancreatic Cancer Drug Shines in Early-Stage Study
The data was presented at the 2018 ASCO Gastrointestinal Cancers Symposium in San Francisco, Calif. today. Source: BioSpace
Why This Seattle Biotech Could be an M&A Target
Immune Design is a clinical-stage immunotherapy company. Source: BioSpace
Heptares Co-Founder Resigns as VP and CSO of Parent Company Sosei
Dr. Marshall will leave Sosei at the end of February 2018. Source: BioSpace
What You Need to Know About Jecure Therapeutics
Jecure Therapeutics, based in San Diego, stated operations in mid-2016 with a focus on NASH and liver fibrosis. Source: BioSpace
- Go to the previous page
- 1
- …
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- …
- 288
- Go to the next page